Southeast Asia Prefilled Syringes Market: Current Analysis and Forecast (2025-2033)

Prefilled syringes are systems of single-dose drug delivery that contain a specific volume of drugs ready to be administered directly. They are to enhance precision, decrease the risk of contamination, and increase patient convenience. They are broadly applicable in cases of vaccines, biologics, and managing chronic diseases, and are easy to administer to the healthcare system and patients.

The Southeast Asian Prefilled Syringes market is expected to exhibit a growth rate of 8.77% during the forecast period (2025-2033F). The primary factors driving the Southeast Asia Prefilled Syringes Market are the rising prevalence of chronic diseases, increasing demand for biologics and biosimilars, and the growing number of vaccinations. The rapid development of healthcare facilities in the region, along with an increased adoption of minimally invasive forms of drug delivery and a shift toward home-based treatments, is also driving growth. Additionally, the growing demand to minimize cross-contamination and reduce dosing errors caused by the use of multiple-use sterile instruments is driving market expansion, facilitated by regulatory efforts to promote safer injectable delivery solutions. Moreover, the increasing demand is forcing local and multinational players to increase their investments.

On April 24, 2025, SCG Packaging Public Company Limited, also known as SCGP, announced that the company is implementing a strategy to enhance its capabilities in the growing healthcare supplies market, which continues to show strong growth potential. This involves entering the syringes and needles market. The company's board of directors approved an investment project to expand syringes production capacity by 180 million units per year and needles production by 100 million units per year at VEM (Thailand) Company Limited (VEM-TH) in SCGP, Rayong Province, with a total investment of Baht 142.3 million (~USD 4.37 million). Production is expected to begin in January 2026.

Based on product type, the market is segmented into staked needle syringe and luer syringe. Among these, the staked needle prefilled syringes market held the largest share in 2024. This is mainly due to its ability to provide ready-to-use, contamination-free solutions that are applicable in mass immunization and chronic care therapies. The integrated design saves on assembly time and ensures the correct dosage is administered, making it very appealing to large-scale healthcare programs. Moreover, with the growth of regional production, producers are embracing automation and safety improvements in order to fulfill the increasing demand in an efficient manner.

Based on material, the Southeast Asian prefilled syringes market is segmented into glass and plastic. Among these, the glass prefilled syringes market held the dominant share of the Southeast Asia Prefilled Syringes market in 2024. Prefilled syringes made of glass still drive market adoption because they have been shown to be compatible with drugs and offer better barrier characteristics. They remain the renewed preference with regard to sensitive biologics and vaccines, and promote pharmaceutical quality and stability specifications. Also, the glass formats are an increasingly popular format of local fill-finish to fulfill the export-grade production and regulatory needs.

Based on design, the market is segmented into single-chamber, dual-chamber, and customized. Among these, the dual-chamber prefilled syringes market is expected to grow at a significant CAGR during the forecast period (2025-2033). This is mainly due to the increasing trend of dual-chamber prefilled syringe innovation, as biologics and lyophilized drugs require careful reconstitution before injection. This segment helps differentiate the products by incorporating the drug and diluent into a single device, thereby providing patients with convenience. With the growing adoption of combination therapies, companies are investing in sophisticated dual-chamber designs to increase their high-value injectable lines.

Based on application, the market is segmented into vaccines, antithrombotic drugs, biologics and biosimilars, autoimmune diseases, and others. Among these, the vaccines segment is expected to grow at a significant CAGR during the forecast period (2025-2033). The segment of vaccines contributes greatly to expanding the market at high speed due to national immunization and pandemic readiness efforts. Vaccines administered in prefilled syringes are quick, secure, and efficient to deliver and minimize wastage as well as enhance logistical management. The manufacturing and distribution capabilities across Southeast Asia are still being enhanced due to the government support of syringe-based vaccination campaigns.

For a better understanding of the market adoption of the Southeast Asian Prefilled Syringes market, it is analyzed based on its regional presence in Southeast Asia, including Indonesia, Thailand, the Philippines, Vietnam, Malaysia, Singapore, and the Rest of Southeast Asia. Vietnam is expected to grow at a significant CAGR during the forecast period (2025-2033). This is mainly due to increasing healthcare investments and growing vaccination programs that drive the markets for prefilled syringes in the region. The emphasis of the government on local pharmaceutical manufacturing and production of medical devices has promoted the use of technologies and foreign collaboration. However, the rise in chronic disease and increased imports of biologics are putting a strain on high-quality injectable formats. Therefore, domestic companies are upgrading the sterile, ready-to-fill syringe production lines to meet both national and overseas demand. As foreign direct investment continues to increase and regulatory controls are enhanced, Vietnam is establishing itself as a competitive manufacturing platform. All these developments contribute to the fact that Vietnam is a strategic growth engine in the prefilled syringes industry in Southeast Asia. On April 3, 2025, RV Group announced a USD 20 million investment in an EU/WHO-GMP compliant sterile injectable (aseptic) facility at its existing OPO Vietnam location, representing the first advanced manufacturing hub for oncology and biosimilars in Vietnam. The facility will use ready-to-use prefilled syringes, vials, stoppers, and caps with a single combined line machine with a robotic arm system for operations.

Some major players running in the market include Becton Dickinson Holdings Pte Ltd (BD), NIPRO Corporation, WuXi Biologics, Terumo Corporation, SCHOTT Pharma (SCHOTT AG), Sandoz Singapore Pte. Ltd. (Sandoz Group AG), West Pharmaceutical Services, Inc., Weigao Medical International Co., Ltd (Weigao Group), Gerresheimer AG, PT Etana Biotechnologies Indonesia.